PROMOTE: Effects of 5-HT4 Agonism on Cognition and Sleep in Peopl With Low Mood (PROMOTE)

November 6, 2026 updated by: University of Oxford

Investigating the Effect of 5-HT4 Receptor Agonism on Cognition and Sleep in People With Low Mood

Serotonin is a chemical in the brain that plays an important role in mood, sleep, and other functions. It works by attaching to different types of serotonin receptors on brain cells. These receptors act like "locks", with serotonin acting like a "key". Different types of serotonin receptors have different effects in the brain.

Prucalopride is a licensed medication used to treat constipation. It acts on a particular serotonin receptor, called the serotonin 4 receptor. Researchers are interested in this receptor because understanding how it works in the brain may help us learn more about depression and could contribute to the development of new treatments in the future.

The purpose of this study is to investigate the effects of prucalopride in people experiencing low mood. We will compare prucalopride with a placebo (a treatment with no active medication) to find out whether activating the serotonin 4 receptor affects sleep and aspects of thinking, including memory, attention and decision making.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Cognitive symptoms are common in depression and can persist even when other symptoms of depression have improved. These difficulties can include impairments in memory, attention and executive function, and there remains a need for treatments that specifically target cognitive dysfunction associated with depression.

Evidence from preclinical and human experimental studies suggests that activation of the serotonin 4 receptor (5-HT4R) may represent a potential therapeutic approach for targeting cognitive symptoms in depression. The 5-HT4R is expressed in brain regions involved in learning and memory, and experimental studies have investigated whether selective activation of this receptor can influence cognitive processes relevant to depression.

Prucalopride is a selective 5-HT4R agonist. In previous human experimental studies, we have found evidence that prucalopride can influence cognitive processes, including learning and memory, in healthy volunteers and people who have recovered from depression. The present study extends this work by investigating the cognitive effects of prucalopride in people who are currently experiencing low mood.

The study will use an experimental medicine approach to examine the effects of 5-HT4R activation on cognitive processes relevant to depression. In addition, the study will investigate the effect of prucalopride on sleep architecture. Sleep will be assessed in the home environment using wearable chest patches capable of sleep staging.

The study will provide proof-of-concept evidence regarding the effects of 5-HT4R activation on cognition and sleep in people experiencing low mood. These data will inform the design and feasibility of a future randomised controlled trial evaluating prucalopride in people with depression and cognitive impairment.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Oxfordshire
      • Oxford, Oxfordshire, United Kingdom, OX3 7JX
        • Recruiting
        • Warneford Hospital
        • Principal Investigator:
          • Susannah E Murphy, DPhil
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged between 18-65
  • Male or female
  • Participant is willing and able to give informed consent for participation in the research
  • Body mass index in the range of 18-35 inclusive
  • Current PHQ-9 score in the range of 9-15

Exclusion Criteria:

  • Any current or previous episode of a severe mental illness, other than Depressive Disorder. Comorbid Anxiety disorders will be allowed, but not OCD or PTSD.
  • A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia
  • Body Mass Index outside the range of 18 to 35 inclusive
  • Any significant current medical condition likely to interfere with conduct of the study or analysis of data
  • Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion)
  • Ongoing psychopharmacological treatment for depression, including hypnotics (psychotherapy will be allowed as long as not newly-started in the last 6 weeks)
  • High consumption of illicit substances to an extent that would make complying with study protocol challenging (including alcohol, caffeine, nicotine)
  • Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study
  • Currently pregnant, trying to get pregnant, or breast feeding
  • Current, or a significant history of, gastro-intestinal disorder or irritable bowel syndrome
  • Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose
  • Participation in a study that involves the use of a medication or novel vaccine within the last three months
  • Participation in a study using the same tasks in the last year
  • Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging, including yellow/blue colourblindness
  • A head injury causing concussion or loss of consciousness within the last six months
  • Moderate to high risk of suicide or self-harm
  • Participant who is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Chief Investigator.

Additional Exclusion Criteria for Participants in the Sleep Study Cohort:

  • Unable to undergo cardiac monitoring
  • Unable to wear the sleep patch device for full monitoring period
  • Implanted neurostimulator or pacemaker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Prucalopride

Participants will receive daily oral prucalopride for 14 days.

Prucalopride will be administered orally once daily for 14 days. Participants will receive 1 mg once daily on Days 1-2 and 2 mg once daily on Days 3-14.

Placebo Comparator: Placebo

Participants will receive daily oral placebo for 14 days.

A matching placebo (lactose) will be administered orally once daily for 14 days. Participants will take one placebo capsule on Days 1-2 and two placebo capsules on Days 3-14, matching the dosing schedule of the prucalopride intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Auditory Verbal Learning Test (AVLT)
Time Frame: Day 14 (post-intervention)

Verbal learning and memory will be assessed using the Auditory Verbal Learning Test, including measures of immediate recall, delayed recall, and recognition memory. AVLT performance will be compared between prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sleep outcomes measured using wearable sleep monitoring
Time Frame: Baseline (Day 0) and Days 1-4 of the intervention

Sleep will be assessed using a wearable chest patch in a subset of participants (n=20 total, 10 per intervention group). Measures will include sleep duration, sleep quality and sleep staging. Sleep outcomes will be compared between the prucalopride and placebo groups.

Baseline (Day 0) and Days 1-4 of the intervention
Digit Span Task
Time Frame: Baseline and Day 14 (post-intervention)

Maximum digit span will be assessed as a measure of working memory and compared between the prucalopride and placebo groups

Baseline and Day 14 (post-intervention)
Emotional Go/No-Go (EGNG)
Time Frame: Day 14 (post-intervention)

Inhibitory control will be assessed using the EGNG task, including measures of commission errors, omission errors, and reaction time. Performance will be compared between prucalopride and placebo groups follwing the intervention.

Day 14 (post-intervention)
Probabilistic Reversal Learning Task (PRL)
Time Frame: Day 14 (post-intervention)

Cognitive flexibility and reward-based learning will be assessed using the PRL task, including measures such as response accuracy, reversal errors, and sensitivity to reward and punishment. Performance will be compared between prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)
Mnemonic Similarity Task (MST)
Time Frame: Day 14 (post-intervention)

Pattern separation and recognition memory will be assessed using the MST. Performance will be compared between the prucalopride and placebo groups following the intervention.

Day 14 (post-intervention)
Serial Addition Task (SAT)
Time Frame: Day 14 (post-intervention)

Working memory will be assessed using the SAT. Performance will be compared between the prucalopride and placebo groups following the intervention

Day 14 (post-intervention)
Matrix Span Task
Time Frame: Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.

Visual working memory assessed using the Matrix Span Task, administered remotely via the NeuroUX app. Performance (accuracy/reaction time) will be compared between prucalopride and placebo groups.

Baseline and Days 2, 3, 5, 6, 8, 10, 11 and 13 of the 14-day intervention.
Variable Difficulty List Memory Test (VDLMT)
Time Frame: Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.

Verbal learning and recognition memory will be assessed using the VDLMT, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 2, 4, 6, 7, 9, 11, 12 and 14 of the 14-day intervention.
N-Back Test
Time Frame: Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.

Working memory will be assessed using the 2-back version of the N-back task, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 3, 4, 6, 8, 9, 11, 13 and 14 of the 14-day intervention.
Digit Symbol Substitution Task (DSST)
Time Frame: Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.

Processing speed will be assessed using the DSST, administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 1, 3, 5, 7, 8, 10, 12 and 13 of the 14-day intervention.
Quick Tap 2 Test
Time Frame: Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.

Response inhibition will be assessed using the Quick Tap 2 test, a go/no-go task administered remotely via the NeuroUX app. Performance will be compared between the prucalopride and placebo groups.

Baseline and Days 2, 4, 5, 7, 9, 10, 12 and 14 of the 14-day intervention.
Paired Associates Learning (PAL)
Time Frame: Day 14 (post-intervention)

Verbal associative and episodic memory will be assessed using the PAL task. Performance will be compared between the prucalopride and placebo groups.

Day 14 (post-intervention)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
State Subjective Cognition Scale (SSCS)
Time Frame: Baseline and daily during the 14-day intervention.

Subjective cognitive functioning will be assessed using the State Subjective Cognition Scale (SSCS). Responses will be compared between the prucalopride and placebo groups.

Baseline and daily during the 14-day intervention.
Positive and Negative Affect Schedule (PANAS)
Time Frame: Baseline and daily during the 14-day intervention.

Positive and negative affect will be assessed using the PANAS. Scores will be compared between the prucalopride and placebo groups.

Baseline and daily during the 14-day intervention.
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, Day 7 and Day 14 of the intervention

Depressive symptoms will be assessed using the PHQ-9. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention
Perceived Deficits Questionnaire (PDQ)
Time Frame: Baseline, Day 7 and Day 14 of the intervention

Subjective cognitive difficulties will be assessed using the PDQ. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention
Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline, Day 7 and Day 14 of the intervention.

Anxiety symptoms will be assessed using the GAD-7. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention.
Temporal Experience of Pleasure Scale (TEPS)
Time Frame: Baseline, Day 7 and Day 14 of the intervention.

Anticipatory and consummatory pleasure will be assessed using the TEPS. Scores will be compared between the prucalopride and placebo groups.

Baseline, Day 7 and Day 14 of the intervention.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Susannah E Murphy, DPhil, Department of Psychiatry, University of Oxford

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 10, 2026

Primary Completion (Estimated)

July 1, 2028

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

September 23, 2026

First Submitted That Met QC Criteria

September 23, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

November 9, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • PROMOTE (2544373)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Anonymised individual participant data (IPD) that underlie the results reported in publications arising from this study will be available to researchers upon request, subject to appropriate ethical, data protection and institutional requirements

IPD Sharing Time Frame

Available following the publication of the study results

IPD Sharing Access Criteria

Available to researchers on request, subject to approal by the study team/institution and applicable ethical and data protection requirements

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.